Why Abbott Laboratories (ABT) Shares Are Plunging Today

Abbott Laboratories (ABT) shares declined 8.1% despite reporting second-quarter adjusted earnings per share of $1.26 on revenue of $11.14 billion, both exceeding analyst expectations, driven by robust performance in its Medical Devices segment. The stock's negative reaction primarily stemmed from the company's decision to maintain its full-year 2025 adjusted EPS guidance of $5.10-$5.20, which disappointed investors who had anticipated an upward revision given the strong Q2 results and 7.5% organic sales growth in its base business.

Analysis

Abbott Laboratories (ABT) experienced a significant share price decline of 8.1% despite reporting second-quarter financial results that exceeded analyst expectations. The company posted an adjusted EPS of $1.26 on revenue of $11.14 billion, surpassing consensus estimates of $1.25 and $11.07 billion, respectively. This performance was underpinned by robust growth in its Medical Devices segment, which expanded 13.4% on a reported basis, driven by strong demand for Diabetes Care products like FreeStyle Libre. Despite this quarterly beat and a 7.5% organic sales growth in its base business, the negative market reaction was triggered by the company's decision to maintain its full-year 2025 adjusted EPS guidance of $5.10 to $5.20. This lack of an upward revision appears to have disappointed investors who had anticipated a raised outlook, signaling a potential disconnect between current operational strength and management's forward-looking caution. The magnitude of the stock's decline is particularly noteworthy given its low historical volatility, suggesting the market perceives this guidance decision as a meaningful event.

Key Decisions for Investors

• The 8.1% price drop, driven by unmet guidance expectations rather than a fundamental performance miss, may present a compelling entry point for long-term investors confident in the underlying business strength, particularly in the high-growth Medical Devices segment.
• Investors should scrutinize management's future commentary for any shifts in their outlook, as the decision to hold guidance steady despite a strong Q2 introduces uncertainty about performance expectations for the second half of the year.
• Given the market's clear sensitivity to forward-looking statements, positions should be managed with an awareness of the heightened risk and volatility around future earnings reports and guidance updates.
• Consider the contrast between the stock's positive 5.4% reaction to maintained guidance three months prior and today's negative reaction, which indicates that investor expectations have since escalated and were not met.